

e Application of: Homey et al. : Examiner: Elizabeth Kemmerer

For: Uses of Mammalian Genes

and Related Reagents

Group Art Unit: 1646

Serial No.: 09/995,534

Filing Date: November 27, 2001

RECEIVED

May 7, 2003

MAY 1 2 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

**TECH CENTER 1600/2900** 

### **RESPONSE TO RESTRICTION REQUIREMENT**

This is in response to the Office Action, Paper No. 9, (Confirmation No. 2027) dated April 9, 2003, in the above-identified application, for which a response is due May 9, 2003.

## **Restriction requirement**

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- Claims 10, 13, 14, and 16-26 (all in part), drawn to a methods for treating wounds comprising administering lymphotactin polypeptide, classified in 424, subclass 85.1.
- II. Claims 10 (in part), 13 (in part), 14 (in part), 15, and 16-26 (in part), drawn to a methods for treating wounds comprising administering lymphotactin nucleic acids, classified in 514, subclass 44.

# Response

In response to the present Restriction Requirement, Applicants elect <u>Group I</u> (Claims 10, 13, 14 and 16-26, all in part) with <u>traverse</u>. These claims are directed to methods for treating wounds comprising administering a cytokine <u>polypeptide</u> to accelerate wound healing. As noted in Applicants' February 26, 2003 communication, Applicants had selected <u>lymphotactin</u> among the species of cytokines and cytokine receptors listed by the Examiner in the Office Action, Paper No. 6, dated January 15, 2003.

Although the two groups noted above identify inventions that are independent and distinct, Applicants believe that they are sufficiently related to be examined together without causing undue burden to the Examiner. Both groups are drawn to protein delivery. Group I is directed to delivery of lymphotactin polypeptide. Group II is directed to administration of a nucleic acid that expresses lymphotactin polypeptide. As Group II inherently involves the delivery of lymphotactin polypeptide, Applicants believe it would not be a serious burden for the Examiner to examine Group I together with Group II.

According to MPEP §803, there are two criteria for a proper Restriction Requirement:

- (1) the invention must be independent or distinct as claimed, and
- (2) there must be a serious burden on the examiner if the restriction is not required.

  Moreover,

if the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to distinct or independent inventions.

In conclusion, Applicants respectfully request reconsideration and withdrawal of this Restriction Requirement. Furthermore, Applicants believe that the next step in the prosecution of this Application should be in the form of a Notice of Allowance and respectfully solicit such action.

If the Examiner has any questions regarding this response, she is encouraged to contact the undersigned.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION Patent Department, K-6-1, 1990 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530

Fax: 908-298-5388

Sandy Zaradic, Ph.D. Reg. No. 45,997

Patent Agent for Applicants

(908) 298-7221

9p	16	46
----	----	----

PTO/SB/21 (03-03)

3C64 JULY	U.S. P	Approved for use through 04/30/2003. OMB 0651-0031 alent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE	
FORM	5, no persons are required to respond to a coll Application Number	ection of information unless it displays a valid OMB control number. 09/995,534	
RANSMITTAL	Filing Date	November 27, 2001	
FORM	First Named Inventor	Homey et al.	
wed for all correspondence after initi	al filing) Art Unit	1646	
	Examiner Name	Elizabeth Kemmerer	
Table of Santa In This Coherboles	5 Attorney Docket Number		
Total Number of Pages In This Submission   5   DX01342			
ENCLOSURES (Check all that apply)			
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts/	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application  Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Remarks		
under 37 CFR 1.52 or 1.53		1EON CENTEN 1000/29	
SIGN	ATURE OF APPLICANT, ATTO	RNEY, OR AGENT	
Firm or Individual SANDY ZARADIC, Signature Date May 7, 2003			
	CERTIFICATE OF TRANSMISS	ON/MAILING	
	facsimile transmitted to the USPTO or deposit	ed with the United States Postal Service with sufficient postage as	
Typed or printed			
Signature		Date	

This collection of informetion is required by 37 CFR 1.5. The informetion is required to obtain or retein e benefit by the public which is to file (and by the USPTO to process) en application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed epplication form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No.: DX01342 Application No.: 09/995,534


Filing Date: November 27, 2001

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains a valid OMB control number.



### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

#### **Commissioner for Patents**

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED

MAY 1 2 2003

TECH CENTER 1600/2900

on\_\_\_May 7, 2003

Date

SANDY ZARADIC, Reg. No. 45,997

Typed or printed name of person of signing Certificate

Signature

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents submitted:

Response Transmittal - 1 page

Response to Restriction Requirement - 3 pages

Certificate of Mailing - 1 page

Return Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.